Omega Diagnostics Group PLC Change of preliminary results date (7778V)
August 12 2022 - 2:00AM
UK Regulatory
TIDMODX
RNS Number : 7778V
Omega Diagnostics Group PLC
12 August 2022
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Change of preliminary results date and investor presentation
and update to CD4 sale
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Health & Nutrition products,
provides the following updates regarding the preliminary results
for the year ended 31 March 2022, the investor presentation and the
completion of sale of its CD4 Business, which was announced on the
3 August 2022.
Preliminary results and investor presentation update
The Company's auditors have requested further time to complete
their work ahead of the release of the Company's preliminary
results for the year ended 31 March 2022. The delay is due to a
combination of the Company finalising the accounting adjustments in
respect to the recent CD4 sale and the subsequent impact on
completion of required audit procedures. Consequently, there will
be delay to the release of the results, which will now be issued on
Thursday 1 September 2022.
The investor presentation relating to the preliminary results
which is to be held via the Investor Meet Company platform will now
take place on Thursday 1 September 2022 at 4:30pm BST. The
presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add to
meet Omega Diagnostics Group plc via:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
The Company's Annual General Meeting date remains unchanged and
will be held on 5 October 2022 at 1 Exchange Crescent, Conference
Square, Edinburgh EH3 8UL at 11:00am.
Update on CD4 sale proceeds
Following the finalisation of the CD4 inventory valuation as at
31 July 2022, there has been an upward revision to the estimated
sale proceeds from the originally stated aggregate cash
consideration of up to GBP6.1m, before costs, to up to GBP6.3m.
This results in an increase in the upfront cash payment due to the
Company from GBP1,100,000 to GBP1,315,000, of which GBP463,000 has
already been received. The balance is due to be received within the
next 10 business days.
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Jag Grewal, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore
(Corporate Finance)
Alice Lane/ Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 70 countries and is now focused on
the health and nutrition sector.
www.omegadx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORQFLFFLVLXBBK
(END) Dow Jones Newswires
August 12, 2022 02:00 ET (06:00 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2023 to Apr 2024
